Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
Clinical trial NCT05518994 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05518994
- Sponsor
- Henan Provincial People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2025-12-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.